Clinical trials: Attention Deficit Hyperactivity Disorders
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and 37.5 mg) given to participants daily in the morning compared to placebo in the treatment of adults aged 18 to 55 years diagnosed with ADHD.
- Trial name
- NCT02604407
- Testing
- SHP465 12.5mg capsules (one capsule daily), SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
- Where
- 45 sites in United States
- Volunteers
- 275 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT02466386
- Testing
- SPD489
- Where
- 50 sites in United States
- Volunteers
- 113 people
- Sponsor
- Shire
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Impact of Combined Medication and Behavioral Treatment for ASD & ADHD
Children with comorbid autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) have significantly worse outcomes than those with either ASD alone or ADHD alone.
- Trial name
- NCT03242772
- Testing
- Amphetamine, ESDM informed parent coaching
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
This was a Phase 2b, randomized, double-blind, multicenter, 2-period, 2-treatment, crossover study to evaluate safety and efficacy of CTN SR compared with placebo in adults with ADHD.
- Trial name
- NCT02547428
- Testing
- CTN SR
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
Background: Multiple studies have found Atomoxetine (Strattera) to be efficacious but there is only one published study specifically designed to evaluate its efficacy in school settings.
- Trial name
- NCT00918567
- Testing
- atomoxetine, Behavior Modification Therapy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- State University of New York at Buffalo
Autism, Autism Spectrum Disorder (ASD)
ScanBrit Dietary Intervention in Autism
A growing body of research indicates that dietary intervention excluding foods containing the proteins, gluten and casein, from the diet of children diagnosed with an autism spectrum disorder (ASD) may have a positive effect on…
- Trial name
- ScanBrit (NCT00614198)
- Testing
- Gluten- and casein-free diet
- Volunteers
- 72 people
- Sponsor
- Center for Autisme, Denmark
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.
The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating Attention Deficit Hyperactivity Disorder (ADHD) in adults.
- Trial name
- NCT01873729
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
While the Lisdexamfetamine Dimesylate (SPD489) clinical program has studied the efficacy, safety, and tolerability of SPD489 in treating core symptoms of ADHD in children and adolescents aged 6-17 years and adults aged 18-55…
- Trial name
- NCT01328756
- Testing
- Lisdexamfetamine dimesylate
- Where
- 35 sites in Belgium, Germany and 8 more
- Volunteers
- 314 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Four-week Open-trial Extension TNS for ADHD
The purpose of this study will be to offer children previously randomized to sham treatment in a 5-week double-blind sham controlled study of Trigeminal Nerve Stimulation for ADHD (NCT02155608) an opportunity to receive 4-weeks…
- Trial name
- NCT03870737
- Testing
- Active TNS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, Los Angeles
ADHD
The Reinforcing Mechanisms of Smoking in Adult ADHD
Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit hyperactivity disorder (ADHD) continue to be elevated.
- Trial name
- NCT00573859
- Testing
- ADHD medication
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Irvine
Attention Deficit Hyperactivity Disorder
Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)
This study will assess the frequency of chromosomal abnormalities measured in circulating lymphocytes in treatment-naive children with Attention Deficit Hyperactivity Disorder (ADHD) treated for 3 months with either extended…
- Trial name
- NCT00409708
- Testing
- Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Novartis
Attention-Deficit/Hyperactivity Disorder
Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
The primary objective of this study is to evaluate the maintenance of efficacy, as measured by Adult ADHD Rating Scale with Prompts (Adult ADHD-RS with prompts) and Clinical Global Impression - Severity (CGI-S) scores, through a…
- Trial name
- NCT00877487
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 55 sites in United States
- Volunteers
- 123 people
- Sponsor
- Shire
Neurofibromatosis 1
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
Children with neurofibromatosis type 1 (NF1) commonly suffer from the effects of cognitive, behavioral, and motor impairments. At present, there is no specific treatment for this NF1 complication.
- Trial name
- DoDNAC (NCT04481048)
- Testing
- N-Acetyl cysteine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning…
- Trial name
- NCT02096952
- Testing
- Methylphenidate extended-release liquid formulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
Using Computers to Assist in the Diagnosis and Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed behavioral disorder in children. Prevalence rates in the United States range from 2% to 18% depending on diagnostic criteria and population studied.
- Trial name
- NCT01351064
- Testing
- CHICA ADHD Module
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Indiana University
Attention-Deficit Hyperactivity Disorder
An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to placebo.
- Trial name
- NCT01323192
- Testing
- JNS001
- Where
- 30 sites in Japan
- Volunteers
- 284 people
- Sponsor
- Janssen Pharmaceutical K.K.
ADHD
Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication
The purpose of this study is to see if supplementing calories with Pediasure is effective in maintaining height, weight, and BMI percentiles for young children during 2 years of treatment with ADHD medication.
- Trial name
- NCT00561340
- Testing
- Pediasure, Nutritional counseling
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Nebraska
ADHD, Substance Use Disorders
Integrated Treatment for Adolescents With ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD) exists in 20-50% of the 3 million adolescents annually enrolled in outpatient mental health and substance use treatment.
- Trial name
- CASALEAP IT2A (NCT02420990)
- Testing
- Medication Integration Protocol (MIP), Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- The National Center on Addiction and Substance Abuse at Columbia University
Intermittent Explosive Disorder, Childhood Aggression
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
Children with explosive aggression are often rejected by their peers, placed in special classroom, and contribute to family discord. When psychotherapy and family therapy is unsuccessful, medications are often used.
- Conditions
- Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
- Trial name
- NCT02048241
- Testing
- Parent Management Training, Intuniv
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- New York State Psychiatric Institute